Loading…
About Anxiety — Mental Health.
Generalized anxiety, social anxiety, panic disorder, and related conditions. Affects 1 in 6 people in the UK.
Audited published research per compound. Drill into a pair for the breakdown.
Bar length counts published studies — green marks studies reporting at least one benefit, slate the other studies (no benefit, unclear or harm); labels read benefit studies / all studies.
◆ marks each compound's research score (0-100): how consistently published studies reported a benefit, weighted by study design. It summarises the research, not how well a compound will work for you.
Compounds with published trial evidence for this condition, ranked by strength of evidence. Each result is put in plain terms and comes from the study itself — open “Exact figures” for the published statistics, or follow the study link to read the paper.
| Compound | Evidence strength | What studies found |
|---|---|---|
| AshwagandhaResearch score 60/100 · Moderate | 2 systematic reviews/meta-analyses + 1 randomised trial — 3 studies | 11/15 outcomes showed benefit
|
We publish community results for anxiety only once at least 10 people have reported on the same compound — so no individual report is ever shown. Until then, here is the research side on its own.
Used something for anxiety? Sharing how it went for you helps the next person — it is only ever published as part of a group of 10 or more.
Add your outcomeOpen the original papers, check their methods, and discuss what is relevant with a qualified professional.
Every study behind the numbers above is linked next to its result.
Ordered by strength of evidence, then result direction.
01Transdiagnostic reduction in cortical choline-containing compounds in anxiety disorders: a (1)H-magnetic resonance spectroscopy meta-analysisMaddock RJ, et al. · Molecular psychiatry · 2025Meta-Analysis · matched via Anxiety · PubMed record (CORPUS-A)
PMID 40913113 ↗02Effects of Different Cannabinoid Formulations on Anxiety-Related Disorders, and Tourette Syndrome: A Systematic Review and Meta-AnalysisRaminelli AO, et al. · Cannabis and cannabinoid research · 2025Systematic Review · matched via Anxiety · PubMed record (CORPUS-A)
PMID 40956670 ↗03Effectiveness of Cannabidiol to Manage Chronic Pain: A Systematic ReviewMohammed SYM, et al. · Pain management nursing : official journal of the American Society of Pain Management Nurses · 2024Systematic Review · matched via Anxiety · PubMed record (CORPUS-A)
PMID 37953193 ↗04Psychosocial and medication interventions to stop or reduce alcohol consumption during pregnancyMinozzi S, et al. · The Cochrane database of systematic reviews · 2024Systematic Review · matched via Anxiety · PubMed record (CORPUS-A)
PMID 38682758 ↗05Therapeutic potential of cannabidiol (CBD) in anxiety disorders: A systematic review and meta-analysisHan K, et al. · Psychiatry research · 2024These compounds appear in related research or traditional use. Their position is not a recommendation or ranking. Research scores summarise published studies only.
| L TheanineResearch score 74/100 · Strong | 2 systematic reviews/meta-analyses + 1 randomised trial — 3 studies | 12/12 outcomes showed benefit
|
| Cannabis THCResearch score 0/100 · Mixed/Weak | 1 systematic review/meta-analysis — 1 study | 0/4 outcomes showed benefit
|
| InositolResearch score 0/100 · Mixed/Weak | 1 systematic review/meta-analysis — 1 study | 0/3 outcomes showed benefit
|
| Bacopa MonnieriResearch score 0/100 · Mixed/Weak | 1 randomised trial — 1 study | 0/2 outcomes showed benefit
|
Systematic Review · matched via Anxiety · PubMed record (CORPUS-A)
Outcome summaries extracted from the linked papers' curated records. Educational, not medical advice.
Ordered by strength of evidence, then result direction.
Significantly reduced vs placebo (7 RCTs)
Adults with stress and anxiety · Systematic review · PMID 32630791 ↗Strong evidenceReduced02Anxiety during simulated public speaking — ReducedSignificantly reduced with 300mg CBD vs placebo
Adults with social anxiety · Randomised controlled trial · PMID 22928017 ↗Moderate evidenceReduced03Stress-related anxiety symptoms — ReducedReduced anxiety scores (200mg daily, 4 weeks)
Adults with stress-related symptoms · Randomised controlled trial · PMID 32531951 ↗Moderate evidenceReduced04Subjective anxiety — ImprovedImproved with 300mg daily supplementation
Mildly anxious adults · Clinical study · PMID 29065490 ↗Insufficient evidenceImprovedFigures are reported as published; study designs and populations vary. Works for Us does not interpret results or provide medical advice.